---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-24-000004"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2024-01-23T23:59:59+00:00"
generated_at: "2026-06-06T20:15:03.869667+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# JNJ Q4 2023 revenue $21.4B (+7.3% YoY), adjusted EPS $2.29 (+11.7%)

## Summary
- Q4 sales $21,395M (+7.3% YoY); FY 2023 sales $85,159M (+6.5% YoY).
- Q4 net earnings from continuing ops $4,132M (diluted EPS $1.70, +39.3% YoY).
- Adjusted Q4 net earnings from continuing ops $5,562M (diluted EPS $2.29, +11.7% YoY).
- Innovative Medicine ex-COVID vaccine grew 9.7% in Q4; MedTech grew 13.3%.
- FY 2023 operational sales growth 7.4% total, 8.0% ex-COVID vaccine.

## SEC filing metadata
- accession: 0000200406-24-000004
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2024-01-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040624000004/0000200406-24-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040624000004/jnj-20240123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-24-000004
- JSON: https://secwatch.observer/filing/0000200406-24-000004.json
- Plain text: https://secwatch.observer/filing/0000200406-24-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.